Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2021-09-16 Regulatory Filings
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir invites to a conference call on new clinical data and further studies with MIV-818
Regulatory Filings Classification · 87% confidence The document is an invitation to a conference call to discuss new clinical data (Phase 1b study results for MIV-818) presented at the ESMO congress. It includes details about the drug, the positive findings (stable disease in HCC patients), and logistical information for the call (date, time, phone numbers, streaming link). This format—announcing a discussion about recent results or upcoming events, often including presentation materials availability afterward—is characteristic of a Call Transcript (CT) if it were the transcript itself, or an Earnings Release (ER) if it were financial results. Since this is an invitation to discuss clinical data and future plans, and it is not a full transcript, nor a formal earnings release, it most closely aligns with the context of a conference call announcement. However, the definition for 'Call Transcript' (CT) is 'Full text transcript of company conference calls (like earnings calls with Q&A)'. Since this document is the *invitation* to the call, not the transcript, and it is announcing updates on clinical progress rather than quarterly financials, it doesn't fit perfectly into ER or CT. Given the options, the content is highly specific to a corporate update event. If the call were about earnings, ER would be plausible. Since it's about clinical data and future studies, and it's an announcement inviting participation, it is most likely a precursor to a CT or a specific type of investor update. In the absence of a specific 'Clinical Update Announcement' category, and noting that the content is focused on presenting data and discussing the program, it is often grouped with CTs or ERs. Given the structure (announcement of a call to discuss data), and the fact that it is not a formal financial report (10-K, IR, ER), the closest fit among the provided options that relates to a scheduled discussion event is CT, although it is technically the announcement *for* the CT. However, if we strictly follow the definitions, this is an announcement about an event where data will be discussed. If the document were the transcript, it would be CT. If it were the initial financial highlights, it would be ER. Since it is an invitation to discuss clinical data, and it is not a formal regulatory filing or report, it is best classified as a Call Transcript (CT) if we assume the system often classifies the announcement of a call alongside the transcript itself, or as RNS if it's considered a general announcement. Given the high specificity of the content (detailed clinical update discussion), CT is the most contextually relevant category for this type of event announcement, even if it's not the transcript itself. Re-evaluating: This is an announcement *inviting* people to a call. This strongly suggests it is an announcement about an upcoming event, which often falls under RNS or RPA if it were announcing a report. Since it's announcing a *call*, and not a report publication, RNS is the safest fallback for a non-standard announcement. However, many platforms group these clinical update calls under CT. Given the focus on the call itself, I will lean towards CT as the intended category for call-related materials, but acknowledge the ambiguity. Let's check RPA: 'Announcement regarding the timing, release, or publication of company reports'. This is a call, not a report publication. Let's stick with CT as the most contextually relevant event type, despite it being an invitation rather than the transcript.
2021-09-16 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to June 2021. It contains comprehensive financial summaries (income statements, cash flow, liquidity), management commentary (CEO's address), and detailed updates on clinical development projects. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-08-19 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT' and covers the period 'JANUARY – JUNE 2021'. It contains detailed financial summaries (turnover, EBITDA, earnings per share, cash flow) for both the quarter and the six-month period, alongside management commentary and operational updates. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2021
2021-08-19 English
Medivir stärker affärsutvecklingspotentialen för remetinostat genom omförhandlat flerpartsavtal
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB, dated August 16, 2021, announcing the renegotiation of financial terms for remetinostat. It details a change in royalty/milestone payments to be based solely on future actual revenue distribution upon potential out-licensing or sale. The text explicitly states that this information is being made public according to EU Market Abuse Regulation and includes standard forward-looking statements and company background. This type of announcement, focusing on a significant business/financial agreement or development that is not a full periodic report (like 10-K or IR), a dividend notice, or a management change, fits best under a general business/financial update. Since it is a formal announcement of a material business event (renegotiated contract terms impacting future revenue streams) released via press release, it is most closely aligned with a general Regulatory Filing (RNS) or potentially a Capital/Financing Update (CAP) if the focus was purely on capital structure, but here the focus is on a specific asset deal structure. Given the options, and that it is a formal regulatory disclosure of a material business event, RNS (Regulatory Filings) is the most appropriate general category for non-standard, material press releases, although it could also be argued as a type of business development update not explicitly covered. However, since it is a formal announcement of a material business event disclosed under market abuse rules, RNS is the best fit as a catch-all for significant, non-standard disclosures.
2021-08-16 Swedish
Medivir strengthens the business development potential of remetinostat through renegotiated multi-party agreement
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing the renegotiation of a multi-party agreement concerning the financial obligations related to their drug candidate, remetinostat. It details changes in milestone payments and royalty structures, framed as creating improved business development opportunities. This type of announcement, which concerns strategic business arrangements, financing obligations, or material contracts that impact future financial structure but is not a formal regulatory filing like a 10-K or a specific financial report (like ER or IR), fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were purely informational. However, since it directly addresses the restructuring of financial obligations (milestones and royalties) related to an asset, it strongly aligns with 'Capital/Financing Update' (CAP), as it changes the capital structure's contingent liabilities. It is not an Earnings Release (ER), Interim Report (IR), or a formal Audit Report (AR). Given the focus on restructuring financial obligations tied to an asset, CAP is the most precise fit.
2021-08-16 English
Resolutions at the Annual General Meeting in Medivir on 5 May 2021
AGM Information Classification · 100% confidence The document explicitly details the 'Resolutions at the Annual General Meeting in Medivir on 5 May 2021'. It covers approvals of financial statements, discharge from liability, remuneration decisions, election of the board and auditor, amendments to articles of association, and authorizations for share issues/reductions. These are the core components of proceedings and outcomes from an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2021-05-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.